News | Implantable Cardiac Monitor (ICM) | July 07, 2020

Next Generation Medtronic ICM Offers Remote Programming and Improved Longevity

Linq II system allows continuous cardiac monitoring for 4.5 years

The Linq II implantable cardiac monitor (ICM) system delivers improved device longevity compared to other ICMs and enhanced accuracy to correctly detect abnormal heart rhythms, simplifying the diagnosis and monitoring of patients. The new devices allows continuous cardiac monitoring for up to 4.5 years.

The Linq II implantable cardiac monitor (ICM) system delivers improved device longevity compared to other ICMs and enhanced accuracy to correctly detect abnormal heart rhythms, simplifying the diagnosis and monitoring of patients. The new devices allows continuous cardiac monitoring for up to 4.5 years.


July 7, 2020 – Medtronic announced it received U.S. Food and Drug Administration (FDA) clearance and European CE mark approval for its Linq II insertable cardiac monitor (ICM) with remote programming, which enables clinicians to optimize device settings without the need for patients to return to the office or hospital. The Linq II system also delivers improved device longevity compared to other ICMs and enhanced accuracy to correctly detect abnormal heart rhythms, simplifying the diagnosis and monitoring of patients. The new devices allows continuous cardiac monitoring for 4.5 years using nominal settings.[1]

Linq II is a small (one-third the size of a AAA battery), wireless ICM for patients with abnormal heart rhythms who experience infrequent symptoms including dizziness, palpitations, syncope (fainting) and chest pain, thereby requiring long-term monitoring or ongoing management. The device will be commercially available in the U.S. and Europe later this summer.

“In the current COVID-19 environment, the Linq II system offers patients a seamless way to experience ongoing connectivity between their device and their physician, while reducing the need for in-office visits,” said Rob Kowal, M.D., Ph.D., chief medical officer of the Cardiac Rhythm and Heart Failure division, which is part of the Cardiac and Vascular Group at Medtronic. “Linq II gives physicians actionable data to help diagnose underlying heart conditions and define treatment protocols for patients with atrial fibrillation (AF) or other abnormal heart rhythms.”

The Linq II device incorporates many of the features of Linq with TruRhythm plus improvements that differentiate the device from other ICMs:
   • Accuracy and Streamlined Workflows: The Linq II device has the lowest published rates of AF false detections compared to previous ICMs.[2-5] It also has an industry exclusive premature ventricular contraction (PVC) detector to help with patient diagnosis; PVCs are extra, abnormal heartbeats that begin in the ventricles, and disrupt the heart rhythm. Additionally, clinicians spend 33 percent less time reviewing ICM transmissions,[6] resulting in potential office efficiencies and reduced costs due to more streamlined workflows.
   • Remote Programming: The Linq II ICM offers remote programming, which reduces the need for patients to come into the office to have their device settings adjusted – a benefit for both patients and physicians, especially during the current COVID-19 pandemic.
   • Remote Patient Management: Patients with the Linq II ICM can choose one of two monitoring options to fit their lifestyles and increase remote monitoring compliance, potentially leading to improved patient outcomes.
   • Patients can use their smartphones to automatically transfer device data via the MyCareLink Heart mobile app using BlueSync technology that
enables secure communication via Bluetooth.
   • Patients who are unable or prefer not to use a cell phone can transmit device data with the MyCareLink Relay Home Communicator.
   • Increased Longevity: The Linq II device offers an extended duration of continuous monitoring at 4.5 years using nominal settings.[1] Continuous monitoring gives physicians greater insights into patient data, aids in diagnoses and helps them manage chronic cardiac arrhythmias.

For more information: www.medtronic.com

References:
1. Linq II Clinician Manual. M974764A001.
2 BiotronikBioMonitor 2 Technical Manual. 2017.
3. NölkerG, et al. J Cardiovasc Electrophysiol. 2016;27:1403-1410. 
4. Confirm Rx ICM DM3500 FDA Clearance Letter. 2017.
5. PürerfellnerH, et al. Europace. 2018;20:f321-f328 
6. Alert Analysis for Linq II with TruRhythm and Linq II, Medtronic data on file, 2020.

 

Related Content

News | Atrial Fibrillation

July 29, 2022 — A cohort study of persons with incident atrial fibrillation (AF) has found that AF after noncardiac ...

Home July 29, 2022
Home
News | Atrial Fibrillation

July 20, 2022 — CardioFocus, Inc., a medical device company dedicated to advancing ablation treatments for atrial ...

Home July 20, 2022
Home
News | Atrial Fibrillation

July 6, 2022 — Atrial fibrillation (AF) is a prevalent cardiovascular condition with one of the highest rates of ...

Home July 06, 2022
Home
News | Atrial Fibrillation

June 30, 2022 — A new onset of a rapid or irregular heartbeat that develops after surgery, often within a few days, is ...

Home June 30, 2022
Home
News | Atrial Fibrillation

May 17, 2022 — Results of a new study reveal Black patients hospitalized with atrial fibrillation (AF) are under ...

Home May 17, 2022
Home
News | Atrial Fibrillation

May 17, 2022 — Results from a new study show success of intended same day discharge (SDD) improves over time for ...

Home May 17, 2022
Home
News | Atrial Fibrillation

May 17, 2022 — On the heels of its landmark valvular heart disease (VHD) prevalence abstract published in Journal of the ...

Home May 17, 2022
Home
News | Atrial Fibrillation

May 2, 2022 – Johnson & Johnson MedTech have announced that Biosense Webster, Inc., a worldwide leader in the science ...

Home May 02, 2022
Home
News | Atrial Fibrillation

April 12, 2022 – iRhythm Technologies, Inc., a leading digital healthcare solutions company focused on the advancement ...

Home April 12, 2022
Home
News | Atrial Fibrillation

April 1, 2022 — Cardiologs announced a poster presentation at the 2022 American College of Cardiology (ACC) meeting in ...

Home April 01, 2022
Home
Subscribe Now